FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study. PMID 38181312 · J Clin Oncol · 2024-Apr-10 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (PFS). The abstract reports original results from the trial. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Community Health workers United to Reduce Colorectal cancer and cardiovascular disease among people at Higher risk (CHURCH): study protocol for a randomized controlled trial. PMID 38659874 · Res Sq · 2024-Apr-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma. PMID 38594603 · BMC Cancer · 2024-Apr-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit. PMID 38587062 · Acta Oncol · 2024-Apr-08 The study is a randomized, oncology trial with drug intervention and time-to-event endpoints, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, which is required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma]. PMID 38599641 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2024-Apr-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial. PMID 38490230 · Lancet · 2024-Apr-06 The trial is a Phase III randomized oncology study with a drug-containing intervention, but its primary efficacy endpoint is health-related quality of life, not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, nor does the abstract report Kaplan-Meier curves or hazard ratios for such an endpoint. Therefore, it does not meet the cohort criteria. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The therapeutic efficacy and mechanism action of Si Cao formula in the treatment of psoriasis: A pilot clinical investigation and animal validation. PMID 38160866 · J Ethnopharmacol · 2024-Apr-06 The study is a randomized pilot clinical trial in psoriasis, a non-oncologic condition. While it is a human, randomized trial with a drug intervention and reports primary efficacy results (PASI, DLQI, recurrence rate), it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hepatopancreaticobiliary Resection Arginine Immunomodulation (PRIMe) trial: protocol for a randomised phase II trial of the impact of perioperative immunomodulation on immune function following resection for hepatopancreaticobiliary malignancy. PMID 38580363 · BMJ Open · 2024-Apr-05 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Standardised training for endoscopic mucosal resection of large non-pedunculated colorectal polyps to reduce recurrence (*STAR-LNPCP study): a multicentre cluster randomised trial. PMID 38216328 · Gut · 2024-Apr-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. PMID 38598571 · N Engl J Med · 2024-Apr-04 The study is a randomized, noninferiority trial with a primary time-to-event endpoint (recurrence-free survival) and reports original results. However, it does not involve a drug-containing intervention (comparing surgical approaches with adjuvant therapies per guidelines) and the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, which only lists 'Equivalence Trial' as a publication type. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study. PMID 38366886 · Oncologist · 2024-Apr-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic liver resection versus radiofrequency ablation for small hepatocellular carcinoma: randomized clinical trial. PMID 38650579 · Br J Surg · 2024-Apr-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study. PMID 38608150 · Br J Surg · 2024-Apr-03 The study is a single-arm Phase II trial evaluating feasibility, safety, and tumor response. It lacks randomization, is not Phase III, and does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol for a pragmatic randomised controlled trial of comparing enhanced acceptance and commitment therapy plus (+) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial. PMID 38566197 · Trials · 2024-Apr-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics. PMID 38565955 · Commun Biol · 2024-Apr-02 This is a methodological research article that applies a new computational framework to data from a Phase III trial. It is not the original primary report of that trial's results. Therefore, it does not meet the core requirement of being an 'original formal-result report' of a randomized trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations. PMID 38592722 · JAMA Netw Open · 2024-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. PMID 38433347 · Clin Cancer Res · 2024-Apr-01 The study is a randomized oncology trial with drug intervention and reports time-to-event endpoints (PFS, OS). However, the primary endpoint is objective response rate (ORR), a non-time-to-event endpoint. Furthermore, the abstract does not explicitly state the trial phase (e.g., Phase III); it describes a subprotocol of a larger trial (NCI-MATCH). The metadata and abstract lack definitive evidence for Phase III/IIIb or Phase II/III status. Therefore, it fails the phase requirement and the primary endpoint requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. PMID 38381994 · J Clin Oncol · 2024-Apr-01 The record describes the pivotal Phase III randomized controlled trial (EMERALD) for elacestrant in advanced/metastatic breast cancer, with PFS as the primary time-to-event endpoint and OS as a secondary endpoint. It is an original report of trial results leading to FDA approval. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | no_km 0 Figure · 0 Panel · risk not_applicable |
| Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. PMID 38353966 · JAMA Surg · 2024-Apr-01 While the study is a randomized, oncology, human trial with a time-to-event endpoint and includes drug interventions as part of the bundle, it is not a Phase III/IIIb or Phase II/III randomized trial of a specific drug intervention against a control. It is an implementation science trial focused on improving adherence to a care bundle. The phase is not specified as definitive drug-development phase III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). PMID 38289994 · Clin Cancer Res · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of cognitive behavior therapy based on the health education pathway on psychology of papillary thyroid carcinoma patients: a randomized controlled trial. PMID 38247574 · Nucl Med Commun · 2024-Apr-01 The record is an oncology, human, randomized trial with original results, but it fails eligibility due to lack of a drug intervention and a time-to-event efficacy endpoint. The study evaluates a cognitive behavioral therapy intervention on psychological outcomes, not a drug on survival or progression endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. PMID 38236580 · Clin Cancer Res · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. PMID 38236575 · Clin Cancer Res · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. PMID 38215358 · J Clin Oncol · 2024-Apr-01 This is a randomized Phase III trial (based on the large sample size of 1,033 patients, randomized design, and definitive comparison of treatment regimens) evaluating a drug-containing intervention (GO with chemotherapy) for human oncology (AML), with primary and key secondary time-to-event efficacy endpoints (OS and EFS). It reports formal results, not a subgroup-only or secondary analysis. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 8 Panel · risk visible |
| Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial. PMID 38211641 · Int J Radiat Oncol Biol Phys · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. PMID 38190578 · J Clin Oncol · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial. PMID 38160916 · Int J Radiat Oncol Biol Phys · 2024-Apr-01 The report is a Phase III randomized trial in prostate cancer (oncology, human). It is an original result of a primary analysis. However, it does not involve a drug-containing intervention; it evaluates a radiation therapy technique (MRgRT) versus standard radiation. Furthermore, the primary endpoint is acute toxicity, not a time-to-event efficacy endpoint like OS, PFS, etc., and no Kaplan-Meier curves or hazard ratios for such endpoints are reported. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Low or High Physical Activity Level Does Not Modulate Prostate Tumor Tissue Protein Synthesis Rates. PMID 38079310 · Med Sci Sports Exerc · 2024-Apr-01 The study is a randomized controlled trial in human prostate cancer patients, but it is not a Phase III/IIIb or Phase II/III trial. It lacks a drug intervention (physical activity is not a drug), and the primary endpoint is tissue protein synthesis rates, which is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.). Therefore, it does not meet the eligibility criteria for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. PMID 38009662 · Cancer · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of Laparoscopic and Open Pancreaticoduodenectomy for Pancreatic or Periampullary Tumors: Three-year Follow-up of a Randomized Clinical Trial. PMID 37965767 · Ann Surg · 2024-Apr-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial. PMID 37929952 · Am J Gastroenterol · 2024-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intensity-Modulated Radiation Therapy Alone Versus Intensity-Modulated Radiation Therapy and Brachytherapy for Early-Stage Oropharyngeal Cancers: Results From a Randomized Controlled Trial. PMID 37660737 · Int J Radiat Oncol Biol Phys · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology-KROG/RTOG 1119 Phase 2 Randomized Trial. PMID 37506981 · Int J Radiat Oncol Biol Phys · 2024-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial. PMID 37433376 · Int J Radiat Oncol Biol Phys · 2024-Apr-01 The study is a single-arm, prospective feasibility trial for adjuvant chemoradiation in breast cancer. It is oncology-related, human, and includes a drug intervention, but it is not randomized, does not report a definitive Phase III or Phase II/III trial phase, and its primary endpoints are feasibility and tolerability, not a time-to-event efficacy outcome like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial. PMID 38659392 · Cancer Med · 2024-Apr The record describes a retrospective, propensity score-matched analysis of a prior prospective randomized trial, comparing 6 vs. 4-5 cycles of chemotherapy. It is not the primary report of a randomized trial. The phase is not explicitly confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized clinical trial: Efficacy of group-based acceptance and commitment therapy program for breast cancer patients with high fear of progression. PMID 38653573 · Psychooncology · 2024-Apr The study is a randomized controlled trial in human oncology (breast cancer) with original results, but it is excluded because: 1) the intervention is non-drug-only (psychological therapy), and 2) the endpoints are not time-to-event efficacy outcomes (no OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. PMID 38635934 · JCO Precis Oncol · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance. PMID 38635932 · JCO Precis Oncol · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. PMID 38633125 · EJHaem · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial. PMID 38629255 · Cancer Med · 2024-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma. PMID 38617599 · JHEP Rep · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase 1 randomized trial of inpatient high-intensity interval training after major surgery. PMID 38583906 · J Gastrointest Surg · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical study on simultaneous resection of liver metastases combined with hyperthermic intraperitoneal chemotherapy for synchronous colorectal cancer liver metastasis. PMID 38583892 · J Gastrointest Surg · 2024-Apr The record describes an oncology, human, randomized trial with a drug intervention (HIPEC) and reports a time-to-event efficacy endpoint (overall survival with HR). However, the trial phase is not explicitly stated as Phase III, IIIb, or Phase II/III in the provided metadata or abstract. The phase cannot be inferred from the available information, so the 'phase3_or_definitive' criterion cannot be established as true. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Associations of Health Care Utilization and Therapeutic Alliance in Patients with Advanced Cancer. PMID 38574330 · J Palliat Med · 2024-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Development and Evaluation of a Multisource Approach to Extend Mortality Follow-Up for Older Adults With Advanced Cancer Enrolled in Randomized Trials. PMID 38564692 · JCO Clin Cancer Inform · 2024-Apr The record describes a methodological study evaluating mortality follow-up extension for older adults with advanced cancer enrolled in randomized trials, but does not report a drug-containing intervention or a Phase III/IIIb or II/III trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study. PMID 38547895 · Lancet Oncol · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Empowerment-Led Guided Self-Help Intervention for Symptom Burden in Breast Cancer Women Treated With Ovarian Function Suppression: A Randomized Trial Protocol. PMID 38545479 · World J Oncol · 2024-Apr 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM. PMID 38520847 · ESMO Open · 2024-Apr The record describes a pooled analysis of two randomized trials (SQUIRE and JFCM) investigating an association between a biomarker (skin toxicity) and efficacy. This is a secondary/post-hoc analysis, not the original primary result report of a single randomized trial's pre-specified primary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial. PMID 38516100 · EClinicalMedicine · 2024-Apr The trial is for COVID-19, not a human malignant neoplasm. The primary outcome is clinical deterioration on an ordinal scale, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) for oncology. It also does not specify a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial. PMID 38516099 · EClinicalMedicine · 2024-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |